Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
11 hedge funds and large institutions have $1.76M invested in Zivo Bioscience, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
2% more capital invested
Capital invested by funds: $1.72M → $1.76M (+$35K)
8% less funds holding
Funds holding: 12 → 11 (-1)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$56.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.4K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$2.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$38.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$12K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$5.43K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$40 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $1.22M | -$38.2K | -1,899 | -4% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $378K | +$13.4K | +668 | +4% |
|
|
3
BlackRock
New York
| $66K | +$56.9K | +2,827 | New |
|
|
4
Wells Fargo
San Francisco,
California
| $46K | -$5.43K | -270 | -12% |
|
|
VCA
5
Verdence Capital Advisors
Hunt Valley,
Maryland
| $39K | – | – | – |
|
|
6
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $5K | +$2.11K | +105 | +101% |
|
|
BC
7
Bartlett & Co
Cincinnati,
Ohio
| $4K | – | – | – |
|
|
BCWM
8
Bartlett & Co Wealth Management
Cincinnati,
Ohio
| $3.92K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$12K | -523 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$4K | -168 | Closed |
|
|
11
Fidelity Investments
Boston,
Massachusetts
| – | -$40 | -2 | -29% |
|
ZIVO Hedge Fund Activity: Q2 2022 in Review
11 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q2 2022, worth a combined $1.76M — up 2% from $1.72M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ZIVO and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.
The largest buyer was BlackRock, opening a new position worth an estimated $56.9K. The largest seller was Geode Capital Management, cutting an estimated $38.2K.
- 11 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q2 2022, down from 12 in Q1 2022.
- Funds reported $1.76M of Zivo Bioscience, Inc. Common Stock stock for Q2 2022, up 2% quarter-over-quarter.
- 1 fund opened new Zivo Bioscience, Inc. Common Stock positions in Q2 2022 and 2 closed out, a net change of -1 holder.
- The largest Zivo Bioscience, Inc. Common Stock buyer in Q2 2022 was BlackRock, an estimated $56.9K added.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q2 2022 was Geode Capital Management, an estimated $38.2K sold.
Based on aggregated 13F filings for Q2 2022.